Yposkesi appoints US-based Executive Director for Business Development
With close to 20 years’ biotech and pharma industry experience, Corrie Hultén will spearhead growth opportunities for Yposkesi, as its capacity to manufacture cell and gene therapies for clients expands globally.
Corbeil-Essonnes (near Paris), France, 28 February, 2022 – Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, today announces the appointment of Corrie Hultén as Executive Director, Business Development.
In her new role, Ms. Hultén will strengthen Yposkesi’s presence in the greater Boston (MA) area, home to more than 1.000 biotechs, and attract new business opportunities for its full-service offering in lentiviral vectors & AAV (Adeno-Associated Virus) manufacturing across the East Coast and beyond in the US.
“We are really excited to welcome Corrie to Yposkesi. Her wealth of expertise and networking within the US biotech and pharma industry, as well as market insights, make her a tremendous addition to the team,” said Alain Lamproye, Executive Chairman of Yposkesi. “I firmly believe that her skills and dynamism will contribute significantly to our commercial development and to the wider success of our company.”
Ms. Hultén joins Yposkesi as the company nears completion of its second state-of-the-art commercial production facility, a new global resource for drug developers of cell and gene therapies (C>). C>, a fast-growing field, are a promising class of medicines that offer the possibility of curing conditions with a genetic basis that have few or no other therapeutic options for patients.
The construction of Yposkesi’s second 5.000m2 (50.000 ft²) site, building structure will be completed by July 2022 and operational by mid-2023, is designed for European and American GMP compliance. It will address the shortage in manufacturing capacity for drug developers seeking to advance clinical trials and commercialize new therapeutic drugs.
“I’m very excited to join Yposkesi and be a part of its strong team, who have deep cell and gene therapy manufacturing expertise and experience far beyond many players in the market,” said Ms. Hultén. “As its operational capacities expand, Yposkesi, is poised to make a significant difference in delivering to drug developers the quality and volume of Advanced Therapy Medicinal Products (ATMP) required to treat patients with rare and life-threatening diseases.”
Ms. Hultén has served as Director, Business Development with Porton Advanced and as a Business Development Executive with Patheon. Prior to that, she worked for an international corporation in fine chemicals for five years, following two years in procurement with a B2C product developer and more than seven years in chemistry R&D sourcing and project management. Ms. Hultén studied biotechnology at Harvard University.